论文信息 - 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma - 字舞流文

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

I. Flinn | D. Miklos | C. Jacobson | L. Lekakis | P. Mcsweeney | J. Rossi | S. Neelapu | F. Locke | I. Braunschweig | O. Oluwole | T. Siddiqi | Yi Lin | J. Timmerman | P. Stiff | A. Goy | B. Hill | A. Deol | U. Farooq | J. Chavez | A. Ghobadi | P. Reagan | A. Bot | Yi-zhou Jiang | W. Go | Jenny J. Kim | A. Herrera | J. Muñoz | A. Xue